Has Belin Bodie, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,801 in general payments to Belin Bodie, MD across 73 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Belin Bodie, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Belin Bodie, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Belin Bodie, MD

Dermatology · Mobile, ALNPI 1891798807

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,601 of the $1,801 with a category attached, or 88.9%. It is spread thinly across 20 manufacturers, the largest accounting for just 17.8% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for dermatology clinicians in AL, where the typical reported total is $4,251.

$1,801in general payments, 2019–2025

Across 73 payments — averaging $24.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Hill Dermaceuticals, Inc.$320
Johnson & Johnson$317
Pfizer$232
Sun Pharmaceutical Industries Inc.$181
Novartis$125
Ortho Dermatologics, A Division Of Bausch Health US, LLC$119
plus $507 from 14 others

$15,516in research payments, 2019–2025

Across 1 payment — averaging $15,516 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

UCB SA$16K

What the payments were for

Food & beverage$1,60189%
Education$20011%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Hill Dermaceuticals, Inc.	5	$320
Johnson & Johnson	9	$317
Pfizer	19	$232
Sun Pharmaceutical Industries Inc.	8	$181
Novartis	1	$125
Ortho Dermatologics, A Division Of Bausch Health US, LLC	2	$119
Paratek Pharmaceuticals, Inc.	6	$87
Lilly USA, LLC	3	$60
Hologic Sales And Service, LLC	2	$41
Cipher Pharmaceuticals US LLC	1	$37
Almirall LLC	2	$37
Dermavant Sciences, Inc.	2	$35
Boehringer Ingelheim	2	$34
Amgen	1	$31
Sanofi	1	$31
Galderma Laboratories, L.p.	2	$30
Organon	4	$28
AbbVie	1	$21
Hartmann USA, Inc.	1	$18
UCB, Inc.	1	$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Tolak$236
COSENTYX$125
DUOBRII$106

How this compares

$1,801 in reported general payments places this provider in the 35th percentile of 168 dermatology providers in Alabama.

See all dermatology providers in Alabama →

Medicare billing

Part B allowed, 2024

$104,609

Medicare patients

389

Services billed

1,777

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Cosentyx Sensoready (2 Pens)Secukinumab	13	$140,556
Betamethasone Dipropionate	109	$3,778
Ketoconazole	232	$3,690
Triamcinolone Acetonide	147	$2,153
Metronidazole	25	$1,827
Mupirocin	180	$1,662
Fluorouracil	15	$1,284
Doxycycline Hyclate	99	$1,168
Clindamycin Phosphate	40	$1,102
Clobetasol Propionate	19	$1,082
Tacrolimus	13	$1,081
ValacyclovirValacyclovir Hcl	32	$826
Fluocinolone Acetonide	13	$682
Nystatin	45	$623
Permethrin	17	$592

Paid to pharmacies, not to this prescriber.

Other dermatology in Mobile

John VanloockMobile$1.4M
Thomas BenderMobile$142K
Ryan RamagosaMobile$87K
Kathryn DempseyMobile$48K
Virginia ReederMobile$22K
Angel AllenMobile$11K
Dena HowellMobile$8K
James KrellBirmingham$944K
Julie HarperBirmingham$920K
Eric BaumGadsden$896K

See the full list for Alabama →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →